| | | | | |
Univariate
|
Multivariate
|
|---|
| |
No. of patients
|
Follow up (years)
|
No. of events
|
Rate
|
HR
|
p
|
HR (95% CI)
|
p-value
|
|---|
|
Total
|
3279
|
6968
|
142
|
2.04
| | | | |
|
Sex
|
|
Male
|
2307
|
4992
|
105
|
2.10
| | | | |
|
Female
|
972
|
1976
|
37
|
1.87
|
0.89
|
0.527
|
1.07 (0.73, 1.57)
|
0.732
|
|
Age at entry of TAHOD (years)
|
|
< = 30
|
1103
|
2270
|
40
|
1.76
| | | | |
|
31~40
|
1401
|
3016
|
50
|
1.66
|
0.95
|
0.812
|
0.86 (0.57, 1.32)
|
0.497
|
|
41+
|
775
|
1682
|
52
|
3.09
|
1.78
|
0.006
|
1.79 (1.18, 2.71)
|
0.006
|
|
Reported mode of infection
|
|
Heterosexual contact
|
2288
|
5013
|
97
|
1.94
| | | | |
|
Homosexual contact
|
614
|
1261
|
12
|
0.95
|
0.47
|
0.014
|
0.68 (0.21, 1.25)
|
0.368
|
|
Injecting drug use
|
132
|
276
|
14
|
5.08
|
2.54
|
0.001
|
1.40 (0.27, 2.53)
|
0.772
|
|
Blood products
|
120
|
196
|
7
|
3.58
|
1.77
|
0.144
|
1.57 (0.26, 3.44)
|
0.721
|
|
Other/unknown
|
125
|
222
|
12
|
5.40
|
2.65
|
0.001
|
1.63 (0.12, 3.01)
|
0.883
|
|
CD4 count (cells/μL) *
|
|
< = 50
|
316
|
268
|
51
|
19.02
| | | | |
|
51–100
|
325
|
246
|
16
|
6.49
|
0.35
|
<0.001
|
0.37 (0.21, 0.66)
|
0.001
|
|
101–200
|
939
|
875
|
20
|
2.29
|
0.12
|
<0.001
|
0.14 (0.08, 0.24)
|
<0.001
|
|
201–300
|
1238
|
1276
|
19
|
1.49
|
0.08
|
<0.001
|
0.10 (0.06, 0.17)
|
<0.001
|
|
301+
|
2242
|
4244
|
22
|
0.52
|
0.03
|
<0.001
|
0.04 (0.02, 0.07)
|
<0.001
|
|
Not tested
|
68
|
59
|
14
|
23.68
|
1.18
|
0.592
|
0.86 (0.46, 1.58)
|
0.622
|
|
Country of TB burden
|
|
High
|
1990
|
3775
|
95
|
2.52
| | | | |
|
Low/intermediate
|
1289
|
3193
|
47
|
1.47
|
0.62
|
0.007
|
0.86 (0.60, 1.26)
|
0.435
|
|
Antiretroviral treatment *
|
|
No treatment
|
830
|
1006
|
44
|
4.37
| | | | |
|
Treated, 0~90 days
|
475
|
88
|
8
|
9.14
|
1.89
|
0.103
|
1.08 (0.50, 2.35)
|
0.846
|
|
Treated, 91–180 days
|
703
|
154
|
5
|
3.24
|
0.67
|
0.405
|
0.39 (0.15, 0.99)
|
0.049
|
|
Treated, 181–360 days
|
1048
|
428
|
21
|
4.91
|
1.06
|
0.838
|
0.73 (0.42, 1.27)
|
0.265
|
|
Treated 361+ days
|
2478
|
5292
|
64
|
1.21
|
0.31
|
<0.001
|
0.32 (0.21, 0.51)
|
<0.001
|
|
Disease stage *
|
|
CDC Category A
|
1444
|
2900
|
37
|
1.28
| | | | |
|
CDC Category B
|
442
|
824
|
12
|
1.46
|
1.15
|
0.679
|
0.95 (0.49, 1.84)
|
0.886
|
|
TB only
|
328
|
634
|
13
|
2.05
|
1.65
|
0.122
|
1.53 (0.80, 2.91)
|
0.197
|
|
TB + CDC Category B
|
202
|
382
|
8
|
2.09
|
1.70
|
0.175
|
0.99 (0.45, 2.16)
|
0.976
|
|
Single non-TB ADI
|
523
|
1035
|
22
|
2.13
|
1.69
|
0.051
|
1.40 (0.80, 2.42)
|
0.237
|
|
Multiple non-TB ADIs
|
212
|
461
|
19
|
4.12
|
3.34
|
<0.001
|
2.27 (1.25, 4.10)
|
0.007
|
|
TB and other ADI(s)
|
336
|
732
|
31
|
4.23
|
3.57
|
<0.001
|
2.12 (1.27, 3.55)
|
0.004
|
- Rate: per 100 person years. HR: hazard ratio. CI: confidence interval. ADI: AIDS defining illness.
- * Time dependent variable, patients can contribute person time to more than one category thus the sum of the categories may be more than the total number of patients.
